Imatinib therapy for chronic myeloid leukemia: Where do we go now?

Journal of Clinical Oncology

Volumn 26, Issue 20, 2008, Pages 3308-3309

  Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; INTERFERON; NILOTINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FORECASTING; HOSPITALIZATION; MALE; MORTALITY; MYELOID LEUKEMIA; NOTE; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORECASTING; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49149121616     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.9870     Document Type: Editorial

References (16)

1. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006
2. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358-3363, 2008
3. Hochhaus A, Kantarjian HM, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007
4. Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007
5. Cortes J, Bruemmendorf T, Kantarjian H, et al: Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML). Blood 110, 2007 (abstr 733)
6. Kantarjian H, Cortes J, Le Coutre P, et al: A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 110, 2007 (abstr 469)
7. Kantarjian H, Talpaz M, O'Brien S, et al: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103:2873-2878, 2004
8. Baccarani M, Martinelli G, Rosti G, et al: Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104:4245-4251, 2004
9. Gardembas M, Rousselot P, Tulliez M, et al: Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 102:4298-4305, 2003
10. Cortes J, O'Brien S, Jones D, et al: Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood 110, 2007 (abstr 30)
11. Cortes J, O'Brien S, Jabbour E, et al: Efficacy of nilotinib (AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CMLCP). Blood 110, 2007 (abstr 29)
12. Aoki E, Kantarjian H, O'Brien S, et al: High-dose imatinib mesylate treatment in patients with untreated early chronic phase chronic myeloid leukemia. J Clin Oncol 24:345s, 2006 (abstr 6535)
13. Hughes TP: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
14. Press RD, Galderisi C, Yang R, et al: A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13:6136-6143, 2007
15. Branford S, Seymour JF, Grigg A, et al: BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13:7080-7085, 2007
16. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58-60, 2007